Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Rs964184 (APOA5-A4-C3-A1) is related to elevated plasma triglyceride levels, but not to an increased risk for vascular events in patients with clinically manifest vascular disease.

van de Woestijne AP, van der Graaf Y, de Bakker PI, Asselbergs FW, Spiering W, Visseren FL; SMART Study Group..

PLoS One. 2014 Jun 30;9(6):e101082. doi: 10.1371/journal.pone.0101082. eCollection 2014.

2.

A functional variant in APOA5/A4/C3/A1 gene cluster contributes to elevated triglycerides and severity of CAD by interfering with microRNA 3201 binding efficiency.

Cui G, Li Z, Li R, Huang J, Wang H, Zhang L, Ding H, Wang DW.

J Am Coll Cardiol. 2014 Jul 22;64(3):267-77. doi: 10.1016/j.jacc.2014.03.050.

3.

Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome.

Wu Y, Yu Y, Zhao T, Wang S, Fu Y, Qi Y, Yang G, Yao W, Su Y, Ma Y, Shi J, Jiang J, Kou C.

PLoS One. 2016 Jan 29;11(1):e0147946. doi: 10.1371/journal.pone.0147946. eCollection 2016.

4.

Triglyceride-raising APOA5 genetic variants are associated with obesity and non-HDL-C in Chinese children and adolescents.

Zhu WF, Wang CL, Liang L, Shen Z, Fu JF, Liu PN, Lv LQ, Zhu YM.

Lipids Health Dis. 2014 Jun 5;13:93. doi: 10.1186/1476-511X-13-93.

5.

Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes.

Qi L, Liu S, Rifai N, Hunter D, Hu FB.

Atherosclerosis. 2007 May;192(1):204-10. Epub 2006 Jun 16.

PMID:
16781717
6.

Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome.

Niculescu LS, Vlădică M, Sima AV.

Biochem Biophys Res Commun. 2010 Jan 1;391(1):587-91. doi: 10.1016/j.bbrc.2009.11.103. Epub 2009 Nov 20.

PMID:
19932084
7.

The -1131 T>C and S19W APOA5 gene polymorphisms are associated with high levels of triglycerides and apolipoprotein C-III, but not with coronary artery disease: an angiographic study.

Martinelli N, Trabetti E, Bassi A, Girelli D, Friso S, Pizzolo F, Sandri M, Malerba G, Pignatti PF, Corrocher R, Olivieri O.

Atherosclerosis. 2007 Apr;191(2):409-17. Epub 2006 May 8.

PMID:
16682041
8.

The Relation between Metabolic Syndrome Risk Factors and Genetic Variations of Apolipoprotein V in Relation with Serum Triglyceride and HDL-C Level.

Fallah MS, Sedaghatikhayat B, Guity K, Akbari F, Azizi F, Daneshpour MS.

Arch Iran Med. 2016 Jan;19(1):46-50. doi: 0161901/AIM.009.

9.

Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.

Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD; ASCOT investigators.; NORDIL investigators.; BRIGHT Consortium..

Am J Hum Genet. 2009 Nov;85(5):628-42. doi: 10.1016/j.ajhg.2009.10.014.

10.

Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome.

Niculescu LS, Fruchart-Najib J, Fruchart JC, Sima A.

Clin Chem Lab Med. 2007;45(9):1133-9.

PMID:
17635078
11.

The APOA5 Trp19 allele is associated with metabolic syndrome via its association with plasma triglycerides.

Dallongeville J, Cottel D, Wagner A, Ducimetière P, Ruidavets JB, Arveiler D, Bingham A, Ferrières J, Amouyel P, Meirhaeghe A.

BMC Med Genet. 2008 Sep 12;9:84. doi: 10.1186/1471-2350-9-84.

12.

Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.

Liu Y, Ordovas JM, Gao G, Province M, Straka RJ, Tsai MY, Lai CQ, Zhang K, Borecki I, Hixson JE, Allison DB, Arnett DK.

Pharmacogenet Genomics. 2009 Feb;19(2):161-9. doi: 10.1097/FPC.0b013e32831e030e.

13.

Relationship between the distribution of plasma HDL subclasses and the polymorphisms of APOA5 in hypertriglyceridemia.

Long S, Chen Z, Han Y, Christopher DM, Zhang C, Yang Y, Tian Y.

Clin Biochem. 2013 Jun;46(9):733-9. doi: 10.1016/j.clinbiochem.2013.03.003. Epub 2013 Mar 13.

PMID:
23499587
14.
15.

Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia.

Mar R, Pajukanta P, Allayee H, Groenendijk M, Dallinga-Thie G, Krauss RM, Sinsheimer JS, Cantor RM, de Bruin TW, Lusis AJ.

Circ Res. 2004 Apr 16;94(7):993-9. Epub 2004 Mar 4.

16.

Association of apolipoprotein A-V concentration with apolipoprotein A5 gene -1131T>C polymorphism and fasting triglyceride levels.

Kim JY, Kim OY, Paik JK, Lee SH, Lee JH.

J Clin Lipidol. 2013 Mar-Apr;7(2):94-101. doi: 10.1016/j.jacl.2012.06.002. Epub 2012 Jun 28.

PMID:
23415427
17.

Impact of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular disease risk in French men.

Dallongeville J, Cottel D, Montaye M, Codron V, Amouyel P, Helbecque N.

Int J Cardiol. 2006 Jan 13;106(2):152-6.

PMID:
16321685
18.

Apolipoprotein A1/C3/A5 haplotypes and serum lipid levels.

Yin RX, Li YY, Lai CQ.

Lipids Health Dis. 2011 Aug 19;10:140. doi: 10.1186/1476-511X-10-140.

19.

Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men.

Delgado-Lista J, Perez-Jimenez F, Ruano J, Perez-Martinez P, Fuentes F, Criado-Garcia J, Parnell LD, Garcia-Rios A, Ordovas JM, Lopez-Miranda J.

J Lipid Res. 2010 Jan;51(1):63-73. doi: 10.1194/jlr.M800527-JLR200.

20.

APOA1/C3/A5 haplotype and risk of hypertriglyceridemia in Taiwanese.

Chien KL, Fang WH, Wen HC, Lin HP, Lin YL, Lin SW, Wu JH, Kao JT.

Clin Chim Acta. 2008 Apr;390(1-2):56-62. doi: 10.1016/j.cca.2007.12.014. Epub 2007 Dec 27.

PMID:
18206649

Supplemental Content

Support Center